Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 434, 137 (10 March 2005) | doi:10.1038/434137a; Published online 9 March 2005
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Group Leader Positions
- The International Iberian Nanotechnology Laboratory (INL)
- Braga Portugal
Carbohydrate Chemistry
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
HIV drug remains unproven without placebo trial
Valendar F. Turner1
- Department of Health, 189 Royal Street, East Perth, Western Australia 6004, Australia
Abstract
Ethical concerns over use of a placebo weaken evidence for the benefits of nevirapine.
While raising concerns about "standards of record keeping" in the HIVNET 012 trial in Uganda, in your News story "Activists and researchers rally behind AIDS drug for mothers" (Nature 432, 935; 2004), you overlook a greater flaw. None of the available evidence for nevirapine comes from a trial in which it was tested against a placebo.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
HIV denialists ignore large gap in the study they citeNature Correspondence (25 May 2006)
A drug is effective if better than a harmless controlNature Correspondence (28 Apr 2005)
Actions of Thrombin and Other Coagulant and Proteolytic Enzymes on Blood PlateletsNature Article (02 Dec 1967)
